bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9%
bluebird bio confirms Ayrmid has not delivered binding offer, shares dive 9%
Key deals this week: xAI acquires X; bluebird bio, Nvidia, Dollar Tree and more
bluebird bio sees higher offer for company from Ayrmid Pharma
bluebird bio stock slides for second day on buyout news
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC
bluebird bio announces take-private deal with Carlyle and SK Capital
40.73MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US09609G2093
CUSIP
09609G100
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
0.32
Book Value
-3.24
Dividend Share
-
Dividend Yield
-
Earnings Share
-24.84
Wall Street Target Price
6.50
EPS Estimate Current Year
0.30
EPS Estimate Next Year
-11.50
EPS Estimate Current Quarter
-6.295
EPS Estimate Next Quarter
-3.8967
Most Recent Quarter
-
Revenue TTM
83,807,000
Gross Profit TTM
-5,573,000
EBITDA
-206,455,008
Profit Margin
-287.23%
Return On Assets TTM
-31.00%
Return On Equity TTM
-295.35%
Revenue Per Share TTM
8.65
Qtly Revenue Growth YOY
391.70%
Diluted Eps TTM
-24.84
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0.4895
Price Book MRQ
0.726
Enterprise Value Revenue
4
Enterprise Value EBITDA
-1
89.11
4.76%629.51
1.44%502.90
1.32%255.35
0.15%249.77
0.12%697.42
0.00%150.70
0.00%568.90
-6.79%78.51
-0.81%156.70
-0.39%